CGL
DNA icon

Clarius Group LLC’s Ginkgo Bioworks DNA Stock Holding History

Clarius Group LLC’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-444
Closed -$5.94K – 460
2024
Q2 		$5.94K Hold
444
– – ﹤0.01% 446
2024
Q1 		$20.6K Hold
444
– – ﹤0.01% 483
2023
Q4 		$30K Hold
444
– – ﹤0.01% 475
2023
Q3 		$32.1K Buy
+444
New +$35.5K ﹤0.01% 459
2023
Q2 		– Sell
-444
Closed -$23.6K – 496
2023
Q1 		$23.6K Hold
444
– – ﹤0.01% 507
2022
Q4 		$30K Buy
+444
New +$40.8K ﹤0.01% 508

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clarius Group LLC's DNA Position: Q3 2024 in Review

Clarius Group LLC sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 444 shares — an estimated $5.94K sold.

Clarius Group LLC first reported a position in DNA in Q4 2022 and held it in 6 quarters. The position peaked at $32.1K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Clarius Group LLC reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Clarius Group LLC sold 444 Ginkgo Bioworks shares in Q3 2024, an estimated $5.94K.
  • Clarius Group LLC first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 6 quarters.
  • Clarius Group LLC's Ginkgo Bioworks position peaked at $32.1K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Clarius Group LLC's 13F filing for Q3 2024, filed 9 Oct 2024.